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Donald Silver, MD,  Columbia, Afro. 
Purpose: Pentoxifylline lessens the metabolic derangements a sociated with ischemia- 
reperfusion i jury. This study evaluated the effects of pentoxif-ylline on platelet-activating 
factor (PAF) production and tissue injury during skeletal muscle ischemia-reperfusion 
injury. 
Methods: The isolated canine gracilis muscle model was used. Group 1 muscles were 
subjected to 5 hours ofischemia nd 20 hours of reperfusion (n = 10); group 2 muscles 
received pentoxifylline, 15 mg/kg, systemic infusion 10 minutes before reperfusion 
(n = 6); group 3 muscles received pentoxifylline, 25 mg/kg, systemic infusion 10 minutes 
before reperfusion (n = 6). PAF was measured from muscle venous effluent by the 
scintillation proximity assay method. Muscle injury was assessed by vital staining and 
planimetry. 
Results: PAF levels in group 2 were decreased at 10, 15, and 30 minutes of reperfusion 
compared with group 1 but did not reach significance. PAF levels in group 3 were 
decreased at all times ofreperfusion compared with group 1 but attained significance only 
at 10 minutes ofreperfusion (p < 0.05). No significant differences in muscle weight were 
noted among the three groups. No differences in the extent of muscle necrosis was 
observed between group 1 (77.26% - 20.38%) and group 2 (60.49% -+ 23.97%) 
(p = 0.08); there was a significant reduction in the extent of muscle necrosis in group 3 
(44.55% + 21.47%) compared with group 1 (to < 0.05). 
Conclusions: The administration of pentoxifylline at 25 mg/kg before reperfusion of 
ischemic skeietal muscle decreased significantly the extent of muscle necrosis and PAF 
levels in the venous effluents at all times ofreperfusion (significantly at 10 minutes). These 
results suggest that pentoxifylline may decrease tissue injury of ischemia-reperfusion by 
inhibiting the production of PAF during critical periods of reperfusion. (J VASC SURG 
1995;21:742-9.) 
Ischemia-reperfusion injury (IRI) has been stud- 
ied extensively, et the precise mediator(s) and the 
pathway(s) by which the mediator(s) exert their 
effect remain unclear. The phenomenon of "no- 
re flow" observed in the microcirculation of reper- 
fused ischemic tissu e appears to play a crucial role in 
the tissue injury. The interaction of the leukocyte 
with the microvascular endothelium ay amplify the 
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injury response by creating an isolated microenviron- 
ment on the endothelial cell surface that is inacces- 
sible to antioxidants and proteolytic enzymes. The 
leukocyte-endothelial cel interaction may also pro- 
duce occlusion of the lumen of the capillaries and 
increase resistance to flow in postcapillary venules.l,2 
Recently, platelet-activating factor (PAF), an endog- 
enous polar lipid that is derived from the membrane 
phospholipids of various cell types, has been impli- 
cated as an important mediator of leukocyte-endo- 
thelial cell interaction i  IRI. 
Pentoxifylline is a methylxanthine that has been 
shown to have numerous hemorheologic effects, 
including inhibition of platelet aggregation and 
increased synthesis/release of prostacyclin. In addi- 
tion, pentoxifylline may alter granulocyte function 
through the inhibition of PAF. 3 Pentoxifylline has 
been shown to lessen the metabolic derangements 
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associated with IRI in the kidney, liver, and brain. 47 
This study was designed to assess the effect of 
pentoxifylline administration tissue injury and on 
PAF production in a skeletal muscle model of IRI. 
MATERIAL/METHODS 
Animal preparation 
Female mongrel dogs weighing 25 to 30 kg were 
conditioned according to the University of Mis- 
souri-Columbia Laboratory Animal Medicine Pro- 
tocol. The isolated canine gracilis muscle model of 
IRI was used in this study. 8With general anesthesia 
and sterile technique, the gracilis muscle was isolated. 
The major vascular pedicle of the gracilis muscle was 
exposed from the femoral vessels to its entrance into 
the muscle. All other pathways of collateral circula- 
tion to the gracilis muscle were interrupted. In 
addition, the origin and insertion sites of the muscle 
were divided and reapproximated to ensure complete 
vascular isolation of the muscle. The gracilis muscle 
was rendered ischemic by application of a nontrau- 
marac vascular clip to the gracilis artery. 
All animals were monitored continuously with an 
electrocardiograph and rectal probe thermometer. 
Body core temperature was maintained between 
37.5 ~ and 38.0 ~ C throughout the study. During 
anesthesia, the animals received normal saline solu- 
tion intravenously at 8 ml/kg/hr. Arterial and venous 
cannulas were placed in the femoral vessels and 
positioned inthe gracilis artery and vein, respectively, 
for blood sampling and continuous pressure mea- 
surements. After 5 hours ofischemia nd 2 hours of 
reperfusion, all cannulas were removed, and the 
wounds were closed. The animals were then awak- 
ened and allowed to recover overnight in an animal 
intensive care facility under the observation of staff 
veterinarians. At 20 hours ofreperfusion, the animals 
were again anesthetized, and the gracilis muscle was 
reexposed. The cannulas were replaced as described 
above for additional blood sampling and pressure 
measurements. At the completion of the protocol, 
the gracilis muscle was harvested, and the animals 
were killed. 
Experimental protocol 
The gracilis muscles were isolated in 22 animals. 
Group i consisted of 10 animals in which the muscle 
was subjected to 5 hours ofischemia followed by 20 
hours of reperfusion. Group 2 consisted of six 
animals in which the muscle was subjected to the 
conditions described above for group 1. Group 2 
muscles received pentoxifylline (Sigma Chemical 
Co., St. Louis, Mo.) 15 mg/kg reconstituted in 100 
ml saline solution. The pentoxifylline solution was 
administered via systemic venous bolus infusion 10 
minutes before reperfusion. Group 3 consisted of six 
animals in which the experimental muscle was 
subjected to the same conditions as described for 
groups 1 and 2; however, pentoxifylline 25 mg/kg 
was administered systemically via bolus infusion 10 
minutes before reperfusion. 
Continuous monitoring of the heart rate and 
mean arterial blood pressure was performed. Venous 
blood samples were obtained from the effluents of the 
gracifis muscles before the onset ofischemia and at 5, 
10, 15, 30, and 60 minutes of reperfusion. An addi- 
tional venous blood sample was obtained at 20 hours 
of reperfusion After obtaining the 20-hour blood 
sample, the muscles were harvested and weighed. 
Each muscle was divided into seven equal sections 
and incubated with reduced mcotinamide adenine 
dinucleotide-nitro blue tetrazolium dye 911 for 20 
minutes at room temperature (25 ~ C). Both sides of 
each muscle section were traced for total area and 
nonstained area (nonviable) with use of planimetry 
(Easydij; Geocomp, Golden,' Colo.). The percentage 
of necrosis of each muscle was calculated on the basis 
of total area, nonstained area, and weight of the 
muscle sections. 
Numerical results are expressed as mean +_ SEM. 
Statistical analysis was performed with the unpaired 
t test and one-way analysis (analysis of variance); 
significance was accepted at levels of 0.05 or less. 
PAF measurements 
Gracilis venous effluent was sampled to obtain 
blood for assay. The levels of PAF were determined 
by scintillation proximity assay. Lipids were extracted 
by the procedure of Bligh and Dyer. 12 The samples of 
venous blood were collected in duplicate in glass test 
tubes containing 10 ~1 of 0.5 mol/L ethylenediamine 
tetraacetic acid (final concentration 5 mmol/L). To 
this 3.75 ml of chloroform-methanol (1:2; V:V) 
was immediately added and the sample mixed well. 
The time between withdrawal of  the blood and the 
addition of the chloroform-methanol mixture was 
less than 30 seconds. The samples were left at room 
temperature for 30 minutes. Next 1.2 ml of chloro- 
form and 1.2 ml of distilled water were added. After 
mixing, the samples were centrifuged atlOOg for 5 
minutes at room temperature. The total lipid was 
extracted by removing the lower phase then drying 
this phase under nitrogen. The samples were resus- 
pended in 100 ~1 of chloroform-methanol mixture 
(1 : 1; vol/vol), and 50 ~1 were placed on silica gel G 
(500 ~m) thin-layer chromatography plates (Uni: 
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plates, Newark, Del.) and developed by use of 
chloroform-methanol-water (65 :35:6) solvent sys- 
tem. Standard PAF (Bachem, Torrence, Calif.) was 
loaded in parallel. The thin-layer chromatography 
plates were dried, and the area corresponding to 
standard PAF was scraped into glass test tubes. A 
chloroform-methanol mixture (1:2; vol/vol) was 
then added to these test tubes containing silica gel 
followed by the addition of chloroform-methanol 
and distilled water as described earlier to isolate the 
total lipids. The lower phase was again dried under 
nitrogen and resuspended in bovine serum albumin. 
The samples were assayed for PAF with the PAF 
[all] scintillation proximity assay system (Amer- 
sham, Arlington Height, Ill.). 13 
RESULTS 
The heart rate in group I muscles did not change 
significantly during ischemia or reperfusion. The 
heart rate in group 2 and group 3 animals increased 
dramatically with the administration fpentoxifylline 
(Fig. 1). This increase was significant during the first 
2 hours of reperfusion, but returned to baseline 
values by 20 hours of reperfusion. No significant 
differences in mean blood pressure were detected in 
any group during the study (Fig. 2). 
The changes in PAF levels during ischemia nd 
reperfusion are depicted in Fig. 3. PAF was decreased 
at 10, 15, and 30 minutes in group 2 compared with 
group 1 muscles; however, these differences did not 
reach statistical significance (p = 0.066,p = 0.320, 
andp = 0.230, respectively). PAF levels in group 3 
muscles were decreased at all times of reperfusion 
compared with group 1 muscles. At 10 minutes of 
reperfusion, the PAF was decreased to 4.89 _+ 5.16 
pmol/ml in group 3 muscles compared with 
41.39 + 9.19 pmol/ml in group 1 muscles (p < 
0.05). In addition, the PAF level at 15 minutes of 
reperfusion was decreased in group 3 muscles 
(10.79 + 3.92 pmol/ml) compared with group 1 
muscles (26.42 -+ 24.46 pmol/ml) but did not attain 
statistical significance (p = 0.08). 
The weight and extent of necrosis for the 
ischemia-reperfused muscles are depicted in Table I. 
No significant differences in weight were noted 
among the three groups. The extent of muscle 
necrosis in group 2 muscles (60.49% - 23.97%) 
was less than that observed in group 1 muscles 
(77.26% +_ 20.38%). This difference did not attain 
statistical significance (p = 0.08). There was, how- 
ever, a significant reduction in the extent of muscle 
necrosis in group 3 muscles (44.55% -- 21.47%) 
compared with group 1 muscles (77.26%_ 
20.38%) (p < 0.05). 
DISCUSSION 
Levels of PAF have been shown to correlate 
directly with tissue injury in models of IRI in the 
liver, 14 gastrointestinal tract, 15,16 and heart. 17 PAF 
antagonists have been shown to exert a protective 
effect on IRI in the brain, kidney, and gastrointestinal 
tract. 18 We have previously shown that PAF is 
significantly increased uring the initial 30 minutes 
ofreperfusion i a skeletal muscle model oflRI. 19 We 
have also been able to simulate the injury observed 
with ischemia-reperfusion by infusing PAF into 
skeletal muscle. 2~ In addition, data are present hat 
suggest that PAF is an important mediator of 
leukocyte-endothelial ce l interaction in ischemia- 
reperfusion i  skeletal muscle.21-2! Pentoxifylline has 
been shown to block the ability of PAF to prime 
leukocytes for enhanced response to subsequent 
stimuli. 3 In this study, the effect of pentoxifylline on 
PAF production by skeletal muscle subjected to IRI 
was evaluated. 
In this study, the heart rate increased significantly 
in group 2 and group 3 muscles with the adminis- 
tration of intravenous pentoxifylline. This increase 
was sustained uring the initial hour of observation 
of reperfusion and returned to baseline by 20 hours 
of reperfusion. No changes in the mean blood 
pressure were observed. Intravenously administered 
pentoxifylline has been shown to be well tolerated in 
several clinical studies without an observed effect on 
the heart rate or the blood pressure. 24 Pentoxifylline 
acts on the adenylcyclase ystem by inhibiting the 
3'-5'-adenosine monophosphate (AMP) phosphodi- 
esterase, which results in a vasodilatory effect. The 
B-receptors are not affected. 25 The mechanism by 
which the administration of pentoxifylline in this 
study caused asignificant tachycardia s unclear. If the 
tachycardia were caused by a vasodilatory effect, one 
would expect the mean blood pressure to have 
decreased significantly after the administration of 
pentoxifylline. 
The administration fpentoxifylline 15 mg/kg via 
systemic venous bolus 10 minutes before autologous 
reperfusion of the ischemic muscle resulted in de- 
creased PAF levels at 10, 15, and 30 minutes of 
reperfusion compared with the control group, but 
these changes did not attain statistical significance. 
The extent of muscle necrosis in this group was also 
decreased compared with the control group, but 
these changes were not statistically significant. The 
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Fig. 1. Heart rate increased Significantly immediately after administratio n f pentoxifylline in 
group 2 and group 3 animals and continued to be significantly elevated uring first 2 hours of 
reperfusion, whereas no changes were observed in: group 1 muscles. Heart rate returned to 
baseline in group 2 and group 3 animals at 20 hours of reperfusion. PRE represents baseline 
measurements before ischemia; PTOX represents pentoxifylline. 
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Fig. 2. No changes in mean blood pressure were observed in any groups during study. PRE 
represents baseline measurements before ischemia; PTOX represents pentoxifylline. 
administration of  25 mg/kg pentoxifylline via sys- 
temic venous bolus 10 minutes before autologous 
reperfusion of ischemic muscle resulted in decreased 
PAF levels at all times of reperfusion compared 
with the control group (significant at 10 minutes; 
p < 0.05). In addition, the extent of muscle necrosis 
was also significantly decreased in this group. 
Pentoxifylline has been shown to lessen the 
metabolic derangements a sociated with IRI in the 
kidney, liver, and brain. 4-7 This study suggests that 
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Fig. 3. PAF levels in group 2 muscles were decreased at 10, 15, and 30 minutes ofreperfusion; 
PAF levels in group 3 muscles were decreased at all time intervals during first hour of  
reperfusion. 
Table I. Muscle weight and necrosis 
Weight (gm) Necrosis (%) 
Group I 128.05 --_ 31.36 77.26 +_ 20.38 
Group 2 157.75 + 42.71 60.49 + 23.97* 
Group 3 134.92 _+ 17.82 44.55 _+ 21.47t 
*p = 0.08 compared with group i/muscles. 
1-p 4.33 • 10 -3 compared with group 1 muscles. 
No differences in the weight of muscles from group 1, group 2, and group 3 were observed. There was less necrosis in group 2 muscles 
compared wtih group i muscles that approached significance. The extent of necrosis in group 3 was significantly decreased when compared 
with group 1 muscles. 
pentoxifylline may exert a protective ffect on skeletal 
muscle subjected to IRI. This beneficial effect may be 
the result of improved microcirculatory blood flow 
during reperfusion of ischemic tissue. 
The administration f pentoxifylline r sults in nu- 
merous effects that, at least heoretically, should im- 
prove the microcirculatory dysfunction observed 
during reperfusion of ischemic tissue. Pentoxifylline 
exerts hemorheologic effects on the red blood cells, 
leukocytes, and platelets resulting in increased efor- 
mability and lower blood viscosity. 2628 The mecha- 
nisms responsible for the increase in cellular deforma- 
bility observed with pentoxifylline administration 
seem related to the increased concentrations of cellu- 
lar adenosine triphosphate, which increases stabiliza- 
tion of the cellular membrane. 29"3~ Several investiga- 
tors have reported a reduction in plasma fibrinogen 
concentration a d an increase in the fibrinolytic activ- 
ity, which decreased red blood cell aggregation and 
improved fluidity of blood during pentoxifylline 
administration. 31-s3 
In vitro studies with human and bovine platelets 
have shown that pentoxifylline increases cAMP levels 
and  inhibits membrane-bound phosphodiesterase. 
These changes activate a protein ldnase, which then 
catalyses the phosphorylation f membrane protein 
by adenosine triphosphate, resulting in inhibition of 
platelet aggregation tendencies. 34 Ex vivo studies 
have demonstrated significantly reduced spontaneous 
and collagen-, adenosine diphosphate-, serotonin-, 
and adrenaline-induced platelet aggregation after 
administration of pentoxifylline in man and mon- 
keys. 3s47 Several studies in animals and human be- 
ings have shown increased prostacyclin levels with 
administration f pentoxifylline, suggesting an addi- 
tional pathway by which pentoxifylline influences 
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platelet function. Increased prostacyclin synthesis 
and release was documented in a rat aorta model with 
pentoxi~lline, a8In vitro studies with isolated bovine 
coronary and human umbilical arteries and veins have 
documented increased prostacyclin after pentoxifyl- 
line administration, a9 Prostacvclin-resistant platelets 
pretreated with pentoxifylline showed normalized 
stimulation response to epmephrine and significantly 
increased cAMP levels. 4~ Healthy volunteers given 
pentoxifylline were shown to have increased 6-oxo- 
PGF7~ (stable derivative of prostacyclin) levels, in- 
creased platelet sensitivity to prostacyclin and PGE7, 
and decreased thromboxane B 2 levels. 4~ There is 
some evidence to suggest that pentoxi ,fvlline may 
"unmask" prostacyclin receptors on the platelet mem- 
brane. 42 
The effect of pentoxifylline on PAF has only 
recently been evaluated. In an ex vivo study with 
granulocytes from healthy volunteers, the stimula- 
tion of neutrophils by N-formyt-methionyMeucyl- 
phenylalanine (FMLP) in the absence ofcytochalasin 
B resulted in the production of minute amounts of 
superoxide dismutase-inhibitable f rricytochrome C
reduction. If the neutrophils were exposed to PAF 
before stimulation with= FMLP, th~[:response iii~ 
creased fourfold. This augmentation, was decreased 
by almost 60% in the resence of pentoxifylline 3P . -  . 
These results:indicate that.:part of  the Protective ffec t 
of pentox@lline during IRI may be caused by 
inhibiting the effect of  P~ on the gr~ulocyte. The 
results of this study indicate that' pentoxifylline 
inhibits thg production- ' of PAF dfiring IRI and 
decreases the extent of muscle necrosis. The mecha- 
nism by which pentoxifylline administration resulted 
in decreased muscle necrosis in this study is purely 
speculative but is probably the result of decreased 
PAF production and inhibition of the: effect of PAF 
on the granulocyte in addition to the previously 
discussed alterations in the microcirculation. 
In conclusion, the administration of pentoxi- 
fylline at 25 mg/kg immediately before reperfusion 
of ischemic skeletal muscle decreased significantly 
the extent of muscle necrosis and PAF levels in the 
venous effluents at all times of reperfusion (sig- 
nificantly decreased at 10 minutes). These results 
suggest hat pentoxifylline decreases the tissue injury 
that occurs during ischemia-reperfusion, perhaps 
by inhibiting the production of PAF during 
critical periods of reperfusion. Further studies to 
evaluate the effect of pentoxifylline administration 
during IRi and, specifically, the effect of pentoxi- 
fylline on granulocyte function during IRI seem 
warranted. 
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DISCUSSION 
Dr. Julie A. Freischlag (Milwaukee, Wis.). This study 
evaluated the effects of intravenously administered pen- 
toxifylline on gracilis muscle tissue necrosis and the 
production of PAF when given after 5 hours of ischemia 
just before reperfusion. This timing of the administration 
of pentoxifylline is appropriate because that is when the real 
window of treatment is available when treating acutely 
ischemic limbs. Less muscle necrosis was seen with the 
lower pentoxifylline dose (15 mg/kg), but the values were 
not significant. However, at the higher dose (25 mg/kg) a 
significant decrease in muscle necrosis was seen. PAF levels 
were reduced at 10, 15, and 30 minutes after administra- 
tion of pentoxifylline 15 mg/kg, again without statistical 
significance, yet the only significant decrease seen with 
pentoxifylline 25 mg/kg was seen at 10 and 15 minutes of 
reperfusion. The authors then conclude that this decrease of 
PAF contributes to the decreased muscle necrosis, possibly 
through aneutrophil activation mechanism by PAF, which 
may be blocked by pentoxifylline. 
The methods are fine and the experiments are well 
thought out. However, I 'm not sure that such a conclusion 
can be drawn with only one 5-minute interval being 
significantly altered, which blunts the whole neutrophil 
response. 
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What is the half-life of PAF? Neutrophils urvive 24 
hours. Can 5 minutes of decreased PAF be significant? 
Where do you think the PAF is originating from? 
Did you measure any other cytokines that may correlate 
with the decreased muscle necrosis? 
Did you measure any neutrophil activity to determine 
whether such a decrease inneutrophil stimulation did occur 
in response to pentoxifylline? 
Did you examine platelet aggregation orother platelet 
studies to determine whether the effect is caused by 
platelets? 
Did you try a larger dose of pentoxifylline to determine 
whether your findings were amplified? 
Dr. John G. Adams. The half-life of PAF is probably 
anywhere from 30 to 60 seconds. 
You make a good point that neutrophils urvive 24 
hours. This significant decrease in our PAF level, which we 
observed in group 3 muscles at 10 minutes of reperfusion, 
accounts for the decreased extent of muscle necrosis purely 
on the basis of blocking PAF production at that one time 
interval. We have performed previous tudies that seemed 
to indicate that the 10- and 15-minute interval of reperfu- 
sion is the critical time period during which PAF exerts an 
effect in this model of IRI, the isolated canine gracilis 
muscle. We are making a leap of faith with our one time 
period in which we are postulating that blockage of PAF at 
this time interval is the reason for the decreased extent of 
muscle necrosis, but previous experiments that we have 
performed in our laboratory seem to indicate that that is 
indeed one of the most critical time periods. 
Where do we think the PAF is originating from? We 
have measured PAF simultaneously from sites other than 
the gracilis muscle effluent and have shown that this does 
appear to be a local phenomenon ofPAF production in the 
muscle. We postulate that probably this production is 
coming from the endothelial cell. We certainly don't have 
any concrete data to support hat. 
We did not measure any other cytokines in this study 
because we were primarily interested in the primary 
modulation and the response to questions concerning 
measuring fimctional neutrophil activity. We have not 
performed functional platelet aggregation studies. Those 
studies are ongoing. 
We did not try any larger doses of pentoxifylline in this 
study. We are currently carrying out those studies. 
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